SG Americas Securities LLC Lowers Stock Position in Immatics N.V. $IMTX

SG Americas Securities LLC cut its stake in shares of Immatics N.V. (NASDAQ:IMTX) by 52.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 99,441 shares of the company’s stock after selling 109,015 shares during the period. SG Americas Securities LLC owned approximately 0.07% of Immatics worth $978,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bank of America Corp DE boosted its position in shares of Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after purchasing an additional 2,231 shares during the period. Quarry LP purchased a new stake in Immatics in the fourth quarter valued at approximately $84,000. Insigneo Advisory Services LLC purchased a new stake in Immatics in the third quarter valued at approximately $103,000. Engineers Gate Manager LP acquired a new position in Immatics during the second quarter worth $124,000. Finally, Fox Run Management L.L.C. purchased a new position in shares of Immatics during the fourth quarter worth $129,000. 64.41% of the stock is owned by hedge funds and other institutional investors.

Immatics Price Performance

Shares of IMTX stock opened at $9.95 on Friday. The firm has a 50 day moving average of $10.47 and a two-hundred day moving average of $10.17. The stock has a market capitalization of $1.33 billion, a PE ratio of -5.00 and a beta of 1.32. Immatics N.V. has a 52 week low of $5.05 and a 52 week high of $12.41.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.08). The company had revenue of $8.81 million for the quarter, compared to analysts’ expectations of $9.79 million. Immatics had a negative return on equity of 47.36% and a negative net margin of 572.35%. Analysts expect that Immatics N.V. will post -1.67 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on IMTX shares. Jefferies Financial Group initiated coverage on Immatics in a research note on Monday, March 16th. They issued a “buy” rating and a $18.00 price objective for the company. Wall Street Zen lowered Immatics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. TD Cowen assumed coverage on Immatics in a report on Tuesday, April 28th. They set a “buy” rating for the company. Chardan Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of Immatics in a research report on Tuesday, May 19th. Finally, Weiss Ratings lowered shares of Immatics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.80.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.